Cargando…

临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理

BACKGROUND AND OBJECTIVE: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is well known as an important technique for diagnosis and staging of lung cancer. But a standard protocol to deal with patients who have a negative pathology result still needs to be defined. Herei...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500495/
https://www.ncbi.nlm.nih.gov/pubmed/31014440
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.04
_version_ 1783415956478885888
collection PubMed
description BACKGROUND AND OBJECTIVE: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is well known as an important technique for diagnosis and staging of lung cancer. But a standard protocol to deal with patients who have a negative pathology result still needs to be defined. Herein, we describe the subsequent procedures of these patients in a single center. METHODS: A total of 1, 412 patients with clinical suspected lung cancer and mediastinal metastasis who underwent EBUS-TBNA were collected between September 2010 and December 2016. Among them, 51 patients with nonspecific pathology result were included and retrospectively analyzed. RESULTS: The 51 patients were stratified into five groups by clinical characterize and follow-up procedures: (1) Diagnosed by other bronchoscopy procedures group (9 cases). Abnormalities of tracheobronchial tree were found during visual examination in the majority of patients (8 cases). Biopsy, endobronchial brushing, bronchoalveolar lavage, and transbronchial lung biopsy (TBLB) were used to get a specific diagnosis. (2) EBUS-TBNA re-biopsy group (11 cases). Patients in this group had normal mucosal appearance and airway lumen. Re-biopsy were performed on patients in this group. (3) Surgery group (6 cases). Patients underwent surgery after negative result of EBUS-TBNA. Five of them were confirmed with non-nodal metastasis after surgery. (4) Underwent other pathology diagnosis group (15 cases). patients in this group had other metastasis sites besides midiastinal lymph node. Computed tomography (CT)-guided fine-needle aspiration and lymph node biopsy were performed. (5) Follow-up group (10 cases). None invasive procedure was used in this group. The median follow up time was 38 months. One patient was diagnosed lymphoma during the follow up. CONCLUSION: Diagnostic procedures should be chosen based on the clinical character in EBUS-TBNA negative patients with suspected lung cancer. Long time follow-up is very important in patients whose diagnosis is apparently unknown.
format Online
Article
Text
id pubmed-6500495
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-65004952019-05-21 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is well known as an important technique for diagnosis and staging of lung cancer. But a standard protocol to deal with patients who have a negative pathology result still needs to be defined. Herein, we describe the subsequent procedures of these patients in a single center. METHODS: A total of 1, 412 patients with clinical suspected lung cancer and mediastinal metastasis who underwent EBUS-TBNA were collected between September 2010 and December 2016. Among them, 51 patients with nonspecific pathology result were included and retrospectively analyzed. RESULTS: The 51 patients were stratified into five groups by clinical characterize and follow-up procedures: (1) Diagnosed by other bronchoscopy procedures group (9 cases). Abnormalities of tracheobronchial tree were found during visual examination in the majority of patients (8 cases). Biopsy, endobronchial brushing, bronchoalveolar lavage, and transbronchial lung biopsy (TBLB) were used to get a specific diagnosis. (2) EBUS-TBNA re-biopsy group (11 cases). Patients in this group had normal mucosal appearance and airway lumen. Re-biopsy were performed on patients in this group. (3) Surgery group (6 cases). Patients underwent surgery after negative result of EBUS-TBNA. Five of them were confirmed with non-nodal metastasis after surgery. (4) Underwent other pathology diagnosis group (15 cases). patients in this group had other metastasis sites besides midiastinal lymph node. Computed tomography (CT)-guided fine-needle aspiration and lymph node biopsy were performed. (5) Follow-up group (10 cases). None invasive procedure was used in this group. The median follow up time was 38 months. One patient was diagnosed lymphoma during the follow up. CONCLUSION: Diagnostic procedures should be chosen based on the clinical character in EBUS-TBNA negative patients with suspected lung cancer. Long time follow-up is very important in patients whose diagnosis is apparently unknown. 中国肺癌杂志编辑部 2019-04-20 /pmc/articles/PMC6500495/ /pubmed/31014440 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.04 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理
title 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理
title_full 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理
title_fullStr 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理
title_full_unstemmed 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理
title_short 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理
title_sort 临床疑诊肺癌纵隔淋巴结转移ebus-tbna阴性患者的处理
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500495/
https://www.ncbi.nlm.nih.gov/pubmed/31014440
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.04
work_keys_str_mv AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ
AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ